Search Results

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024.

Evotec SE announced that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of US$ 20 m to Evotec.

Bristol Myers Squibb announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC to purchase up to five hundred thousand shares of Bristol Myers Squibb’s common stock, representing significantly less than one percent of Bristol Myers Squibb’s common stock outstanding, at an offer price of $55 per share.

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.

Bristol Myers Squibb announced that the company will participate in two upcoming investor conferences in May 2024.

Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the extension application to introduce a new route of administration (subcutaneous use) for Opdivo®.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

Scenic Biotech announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.